KR101098061B1 - 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 - Google Patents

신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 Download PDF

Info

Publication number
KR101098061B1
KR101098061B1 KR1020057005960A KR20057005960A KR101098061B1 KR 101098061 B1 KR101098061 B1 KR 101098061B1 KR 1020057005960 A KR1020057005960 A KR 1020057005960A KR 20057005960 A KR20057005960 A KR 20057005960A KR 101098061 B1 KR101098061 B1 KR 101098061B1
Authority
KR
South Korea
Prior art keywords
gemcitabine
pharmaceutically acceptable
warm
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057005960A
Other languages
English (en)
Korean (ko)
Other versions
KR20050055070A (ko
Inventor
알란 바지
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20050055070A publication Critical patent/KR20050055070A/ko
Application granted granted Critical
Publication of KR101098061B1 publication Critical patent/KR101098061B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
KR1020057005960A 2002-10-09 2003-10-06 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 Expired - Fee Related KR101098061B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy
GB0223380.7 2002-10-09

Publications (2)

Publication Number Publication Date
KR20050055070A KR20050055070A (ko) 2005-06-10
KR101098061B1 true KR101098061B1 (ko) 2011-12-26

Family

ID=9945538

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005960A Expired - Fee Related KR101098061B1 (ko) 2002-10-09 2003-10-06 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도

Country Status (22)

Country Link
US (2) US20060009418A1 (https=)
EP (1) EP1551409B1 (https=)
JP (2) JP5416328B2 (https=)
KR (1) KR101098061B1 (https=)
CN (1) CN100363004C (https=)
AT (1) ATE357236T1 (https=)
AU (1) AU2003269253B2 (https=)
BR (1) BR0315088A (https=)
CA (1) CA2501651C (https=)
CY (1) CY1106601T1 (https=)
DE (1) DE60312715T2 (https=)
DK (1) DK1551409T3 (https=)
ES (1) ES2282656T3 (https=)
GB (1) GB0223380D0 (https=)
IL (1) IL167633A (https=)
MX (1) MXPA05003595A (https=)
NO (1) NO330601B1 (https=)
NZ (1) NZ538999A (https=)
PT (1) PT1551409E (https=)
SI (1) SI1551409T1 (https=)
WO (1) WO2004032937A1 (https=)
ZA (1) ZA200502753B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4608215B2 (ja) 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-3), pages 1080-1081 *

Also Published As

Publication number Publication date
BR0315088A (pt) 2005-08-16
DE60312715D1 (de) 2007-05-03
JP5416328B2 (ja) 2014-02-12
NO20051575L (no) 2005-04-25
CA2501651A1 (en) 2004-04-22
ZA200502753B (en) 2006-03-29
ATE357236T1 (de) 2007-04-15
JP2011088921A (ja) 2011-05-06
KR20050055070A (ko) 2005-06-10
WO2004032937A1 (en) 2004-04-22
SI1551409T1 (sl) 2007-08-31
NZ538999A (en) 2008-02-29
IL167633A (en) 2013-03-24
AU2003269253A1 (en) 2004-05-04
HK1078771A1 (en) 2006-03-24
EP1551409B1 (en) 2007-03-21
US20060009418A1 (en) 2006-01-12
CN100363004C (zh) 2008-01-23
PT1551409E (pt) 2007-05-31
EP1551409A1 (en) 2005-07-13
US20100120708A1 (en) 2010-05-13
NO330601B1 (no) 2011-05-23
CN1703223A (zh) 2005-11-30
DK1551409T3 (da) 2007-06-11
ES2282656T3 (es) 2007-10-16
GB0223380D0 (en) 2002-11-13
DE60312715T2 (de) 2007-12-06
AU2003269253B2 (en) 2007-04-05
JP2006504723A (ja) 2006-02-09
MXPA05003595A (es) 2005-06-03
CA2501651C (en) 2011-02-15
CY1106601T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
KR101098061B1 (ko) 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도
KR20120093411A (ko) 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
KR20070072543A (ko) Ｚｄ6474 및 이마티닙을 포함하는 병합법
KR20080079675A (ko) Ｚｄ6474 및 페메트렉시드의 조합물
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
KR20080077678A (ko) Ａｚｄ2171 및 페메트렉시드의 조합물
AU2006264620B2 (en) Combination therapy of cancer with AZD2171 and gemcitabine
KR20060130764A (ko) 병용 요법
HK1078771B (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of cancer
HK1096023B (en) Combination therapy with azd2171 and 5-fu and/or cpt-11

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20141126

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20151118

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161123

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20171117

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20181115

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191217

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191217